CEBP Infection and Cancer: Biology, Therapeutics, and Prevention Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fang, J.-L.
Right arrow Articles by Lazarus, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fang, J.-L.
Right arrow Articles by Lazarus, P.
Cancer Epidemiology Biomarkers & Prevention Vol. 13, 102-109, January 2004
© 2004 American Association for Cancer Research

Correlation between the UDP-Glucuronosyltransferase (UGT1A1) TATAA Box Polymorphism and Carcinogen Detoxification Phenotype

Significantly Decreased Glucuronidating Activity against Benzo(a)pyrene-7,8-dihydrodiol(-) in Liver Microsomes from Subjects with the UGT1A1*28 Variant

Jia-Long Fang1 and Philip Lazarus1,2,3

1 Departments of Interdisciplinary Oncology, 2 Biochemistry and Molecular Biology, and 3 Pharmacology and Therapeutics, Cancer Epidemiology and Prevention Program, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida

Of the hepatic UDP-glucuronosyltransferases (UGTs), only UGT1A1 and UGT1A9 exhibit activity against benzo(a)pyrene-trans-7R,8R-dihydrodiol [BPD(-)], precursor to the highly mutagenic anti-(+)-benzo(a)pyrene-7R,8S-dihydrodiol-9S,10R-epoxide. The UGT1A1*28 allelic variant contains an additional (TA) dinucleotide repeat in the "TATAA" box [(TA)6>(TA)7] of the UGT1A1 promoter that has been linked to decreased expression of the UGT1A1 gene and decreased bilirubin conjugation, leading to the relatively nondebilitating condition known as Gilbert’s syndrome. To determine whether the UGT1A1 TATAA box polymorphism may play a role in the overall glucuronidation of BPD(-) in humans, we compared UGT1A1 TATAA box genotype with BPD(-) glucuronidating activity in normal liver microsomes. Significant decreases in UGT1A1 protein (P < 0.005) and bilirubin conjugation activity (P < 0.001) were observed in liver microsomes from subjects homozygous for the UGT1A1*28 allelic variant compared with subjects homozygous for the wild-type UGT1A1*1 allele. Significant decreases in BPD(-) glucuronidation activity (P < 0.02) were observed in subjects with the UGT1A1(*28/*28) genotype compared with subjects having the wild-type UGT1A1(*1/*1) genotype in assays of liver microsomes that included 0.1 mM {alpha}-naphthylamine, a competitive inhibitor of UGT1A9 and not UGT1A1. Similar phenotype:genotype correlations were observed when we compared subjects with the UGT1A1(*28/*28) genotype with subjects having the UGT1A1(*1/*28) genotype. In assays with {alpha}-naphthylamine, the Km of liver microsomes against BPD(-) was similar to that reported for UGT1A1-overexpressing baculosomes (319 µM versus 290 µM; Fang et al., Cancer Res., 62: 1978–1986, 2002). These data suggest that the UGT1A1 TATAA box polymorphism plays a role in an individual’s overall ability to detoxify benzo(a)pyrene and in cancer risk.




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
Y. Zheng, D. Sun, A. K. Sharma, G. Chen, S. Amin, and P. Lazarus
Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation
Drug Metab. Dispos., October 1, 2007; 35(10): 1942 - 1948.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
J.-L. Chang, J. Bigler, Y. Schwarz, S. S. Li, L. Li, I. B. King, J. D. Potter, and J. W. Lampe
UGT1A1 Polymorphism Is Associated with Serum Bilirubin Concentrations in a Randomized, Controlled, Fruit and Vegetable Feeding Trial
J. Nutr., April 1, 2007; 137(4): 890 - 897.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. C. Abnet, R. B. Fagundes, P. T. Strickland, F. Kamangar, M. J. Roth, P. R. Taylor, and S. M. Dawsey
The influence of genetic polymorphisms in Ahr, CYP1A1, CYP1A2, CYP1B1, GST M1, GST T1 and UGT1A1 on urine 1-hydroxypyrene glucuronide concentrations in healthy subjects from Rio Grande do Sul, Brazil
Carcinogenesis, January 1, 2007; 28(1): 112 - 117.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. M. Butler, Y. Duguay, R. C. Millikan, R. Sinha, J.-F. Gagne, R. S. Sandler, and C. Guillemette
Joint Effects between UDP-Glucuronosyltransferase 1A7 Genotype and Dietary Carcinogen Exposure on Risk of Colon Cancer
Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1626 - 1632.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
S. Peterson, J. Bigler, N. K. Horner, J. D. Potter, and J. W. Lampe
Cruciferae Interact with the UGT1A1*28 Polymorphism to Determine Serum Bilirubin Levels in Humans
J. Nutr., May 1, 2005; 135(5): 1051 - 1055.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.